Literature DB >> 35680728

Chitosan-Coated Liposomes: The Strategy to Reduce Intestinal Toxicity and Improve Bioavailability of Oral Vinorelbine.

Chen Guo1, Xichun Zhu2, Haoyang Yuan1, Haoyu Liu1, Yu Zhang1, Tian Yin3, Haibing He1, Jingxin Gou4, Xing Tang5.   

Abstract

In recent years, the oral administration of vinorelbine has gradually replaced intravenous administration in the treatment of several types of tumors. Even though the risk of phlebitis is avoided with oral administration, oral vinorelbine is still not a highly patient-compliant route due to the severe gastrointestinal toxicity. Vinorelbine-loaded liposomes with high encapsulation efficiency and suitable particle size were prepared using the ammonium sulfate gradient method. Chitosan-coated liposomes showed the slowest in vitro release compared to uncoated liposomes and vinorelbine solution. No damage was observed in the intestinal epithelial cells of mice orally administered with coated vinorelbine liposomes due to the low presence of the free drug in the gastrointestinal tract and the LD50 was increased from 129.83 to 182.25 mg/kg compared to oral vinorelbine solution. In addition, the positive surface potential of chitosan-coating endowed liposomes with mucosal adhesive function, delaying the time to reach the peak plasma concentration of vinorelbine from 1 to 4 h after administration. And bioavailability was increased to 2.1-fold compared to vinorelbine solution. In short, a new strategy to address the severe gastrointestinal side effects of oral vinorelbine has been developed.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  bioavailability; chitosan-coating; oral liposomes; toxicity; vinorelbine

Mesh:

Substances:

Year:  2022        PMID: 35680728     DOI: 10.1208/s12249-022-02308-7

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  29 in total

Review 1.  Oral versus intravenous vinorelbine: clinical safety profile.

Authors:  Vittorio Gebbia; Christian Puozzo
Journal:  Expert Opin Drug Saf       Date:  2005-09       Impact factor: 4.250

2.  Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.

Authors:  Paul Lesueur; Isabelle Martel-Laffay; Alexandre Escande; Manon Kissel; Chrystel Locher; Radj Gervais; Roland Schott; Alain Vergnenegre; Christos Chouaid
Journal:  Expert Rev Anticancer Ther       Date:  2018-09-17       Impact factor: 4.512

3.  A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.

Authors:  Shih-Hung Yang; Chia-Chi Lin; Zhong-Zhe Lin; Yun-Long Tseng; Ruey-Long Hong
Journal:  Invest New Drugs       Date:  2010-09-01       Impact factor: 3.850

Review 4.  Phospholipids and lipid-based formulations in oral drug delivery.

Authors:  Gert Fricker; Torsten Kromp; Armin Wendel; Alfred Blume; Jürgen Zirkel; Herbert Rebmann; Constanze Setzer; Ralf-Olaf Quinkert; Frank Martin; Christel Müller-Goymann
Journal:  Pharm Res       Date:  2010-04-22       Impact factor: 4.200

Review 5.  [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].

Authors:  Volker Bartsch
Journal:  Onkologie       Date:  2006-03-03

Review 6.  Modified chitosans for oral drug delivery.

Authors:  Martin Werle; Hirofumi Takeuchi; Andreas Bernkop-Schnürch
Journal:  J Pharm Sci       Date:  2009-05       Impact factor: 3.534

7.  Vinorelbine in breast cancer.

Authors:  Jacques Bonneterre; Nicolas Penel
Journal:  Expert Opin Pharmacother       Date:  2008-11       Impact factor: 3.889

8.  Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation.

Authors:  R Urso; C Nencini; G Giorgi; A I Fiaschi
Journal:  Eur Rev Med Pharmacol Sci       Date:  2007 Nov-Dec       Impact factor: 3.507

Review 9.  Adapting liposomes for oral drug delivery.

Authors:  Haisheng He; Yi Lu; Jianping Qi; Quangang Zhu; Zhongjian Chen; Wei Wu
Journal:  Acta Pharm Sin B       Date:  2018-06-20       Impact factor: 11.413

10.  A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption.

Authors:  Tao Wang; Liao Shen; Zhen Zhang; Haiyan Li; Ri Huang; Yadan Zhang; Dongqin Quan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.